Trials / Completed
CompletedNCT06238388
Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients
A Phase I Clinical Trial Exploring the Metabolic and Excretion Characteristics of HSK21542 Injection in Maintenance Hemodialysis Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK21542 Injection | A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed. |
Timeline
- Start date
- 2023-10-10
- Primary completion
- 2023-11-21
- Completion
- 2024-02-27
- First posted
- 2024-02-02
- Last updated
- 2024-08-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06238388. Inclusion in this directory is not an endorsement.